Cardiovascular Diseases in CKD
|
|
- Ambrose Miller
- 6 years ago
- Views:
Transcription
1 1 Cardiovascular Diseases in CKD Hung-Chun Chen, MD, PhD. Kaohsiung Medical University Taiwan Society of Nephrology 1
2 2 High Prevalence of CVD in CKD & ESRD Foley RN et al, AJKD 1998; 32(suppl 3):S112-9
3 3 High CV Mortality in ESRD Foley RN et al, AJKD 1998; 32(suppl 3):S112-9
4 CKD Increased Risks of Death, CV Events & Hospitalization 4 Go AS et al, NEJM 2004;351:
5 5 Cardiorenal Syndrome Ronco C, Contrib Nephrol. 2010;164:33-8
6 Traditional and Nontraditional Risk Factors for CVD in CKD 6 Menon V et al, AJKD 2005;45:223-32
7 Our Findings of Some Nontraditional CV Risk Factors in CKD Patients 7 Cardiac structural changes Heeart Echo Parameters, Surface ECG P wave, bpep/bet (brachial pre-ejection period/ejection time) Framingham risk score Arterial stiffness bapwv (Pulse wave velocity) Four limb BP Volume status Metabolic changes: Hyperuricemia, Anemia, BMI
8 Increased LVMI & Decreased LVEF Correspond with CKD Stages in DM 8 LVMI LVEF LVH LVEF<55% A cross-sectional study enrolled 285 DM with CKD stages 3-5 Chen & Chen, Exp Diabetes Res 2012;2012:789325
9 ECG Parameters are Associated with Increased CV Events in CKD 9 LAD<4.7cm LVEF>55% LAD>4.7cm LVEF<55% HR 2.141, P=0.016 HR 2.007, P=0.028 N=505, Stage 3-5 Chen & Chen, NDT 2012;27:
10 10 Inappropriate LVM is Associated with Increased CV Events in CKD Appropriate LVM Log-rank P = Inappropriate LVM N=485, Stage 3-5 Chen & Chen, Hypertens Res. 2012;35:832-8
11 11 Concentric LVH is Associated with Progression to Dialysis in CKD Non-LVH Concentric LVH Eccentric LVH HR 2.03, P=0.049 A longitudinal study enrolled 415 stage 3-5 Pts Chen & Chen, CJASN 2011;6:2750-8
12 High UA & LVMI are Associated with Rapid Renal Progression & Dialysis 12 N=540, Stage 3-5, Follow 33.4m, Rapid progressor: egfr >-3/y Chen & Chen, Am J Hypertens 2013;26:243-9
13 Anemia & LVH are Associated with Renal Function Decline & CV Events 13 High Hb, LVH(-) Low Hb, LVH(-) High Hb, LVH(+) Low Hb, LVH(+) N=415, Stage 3-5 Chang & Chen, Am J Med Sci 2014; 347:183-9
14 14 High BMI better? Low BMI better?
15 15 Combination of Lower BMI & Higher LVMI is Associated with CV Events in CKD Parameters Unadjusted Multivariate adjusted (1) Multivariate adjusted (2) hazard ratio (95% CI) p hazard ratio (95% CI) p hazard ratio (95% CI) p Higher BMI and lower LVMI Lower BMI and LVMI Higher BMI and LVMI Lower BMI and higher LVMI ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) < ( ) Multivariate model (1): adjusted for age, diabetes mellitus, hypertension, coronary artery disease, atrial fibrillation, systolic blood pressure, and pulse pressure. Multivariate model (2): model (1) + albumin, fasting glucose, log triglyceride, total cholesterol, hemoglobin, egfr, proteinuria, and ACEI and/or ARB use. N=523, Stage 3-5 Chen & Chen, Am J Med Sci :91-6
16 16 Combination of High LAD & Low Albumin is Associated with Renal Function Decline and Dialysis L LAD L LAD H LAD H LAD H Alb L balb H Alb L Alb N=395, Stage 3-5 Chen & Chen, Int J Med Sci 2013;10:575-84
17 17 12-Lead ECG P Wave The 12-lead ECG (P wave morphology, P wave dispersion, P wave duration) is a simple and cheap noninvasive clinical tool to access left atrial enlargement, left ventricular hypertrophy, and left ventricular diastolic dysfunction. Arch Intern Med 1989; 149: Furthermore, P wave parameters were independently associated with increased risks for atrial fibrillation and recurrent transient ischemic attacks. South Med J 2008; 101: Am J Cardiol 107: e911
18 18 High ECG P Wave Dispersion & Maximum P Wave Duration are Associated with Progression to Dialysis & Death Higher P Dispersion Higher Max P Duration N=439, Stage 3-5 Chen & Chen, PLoS One. 2014;9:e101962
19 19 Framingham Risk Score The Framingham Risk Score is a gender-specific algorithm used to estimate the 10-year cardiovascular risk. It contains age, sex, total and HDL cholesterol, BP, smoking.
20 Framingham Risk Score (FRS) in HD: Intermediate Risk Pts have Higher Mortality Rate 20 N=201, Follow 4.4±1.5y Huang & Chen, Nephrology 2013;18:510-5
21 FRS in CKD: ECG Parameters Increased FRS Predictive Power for CV Events 21 Parameters Cardiovascular events FRS AUCs Change in c- statistic FRS + albumin FRS + hemoglobin FRS + egfr FRS + proteinuria FRS + LA diameter > 4.7 cm FRS + LVH FRS + LVEF < 50% Chen & Chen, PLoS One 2013;8:e60008
22 Colin VP System
23 VP ABI, bapwv, bpep/bet 1.ABI/API (Ankle Brachial Pressure Index) Lower extremity artery stenosis Arteriosclerosis Arterial stiffness 2. PWV (Pulse Wave Velocity) Artery stiffness 3. bpep/bet(brachial pre-ejection period/brachilal ejection time) Systolic time interval (STI)
24 24 Good Correlation Between Brachial and ECG Systolic Time Interval (STI) R=0.708, P<0.001 PEP/ET(Pre-ejection period/ejection time): STI N=849, General Chen & Su, PLoS One 2013;8:e55840
25 Higher bpep/bet is Associated with Higher LVMI and Lower LVEF in CKD 25 r = 0.360, P < r = , P < bpep/bet(brachial pre-ejection period/brachilal ejection time): STI N=243, Stage 3-5 Chen & Su, NDT 2011;26:
26 26 bpep/bet is Associated with Increassed CV Events in CKD N=242, Stage 3-5 Chen & Chen, Circ J 2010 ;24;74:
27 27 Both ABI<0.9 & 1.3 are Associated with Overall and CV Mortality in HD and CKD ABI ABI ABI<0.9 ABI<0.9 ABI 1.3 ABI 1.3 Overall Survival Cardiovascular Survival N=69, Stage 3-5, HDN=231 Chen & Chen, Nephrology 2010;15:294-9
28 Either ABI<0.9 or 1.3 is Associated with LVH in CKD 28 N=684, Stage 3-5 Su & Chen, PLoS One 2012;7(9):e44732
29 29 High bapwv is Associated with Rapid Renal Function Decline and Progression to Dialysis and Death in CKD bapwv below Median bapwv above Median egfr Slope Combined end point-free Survival bapwv: brachial artery Pulse Wave Velocity (Arterial stiffness) N=145, Stage 3-5, Follow 14m Chen & Chen, CJASN 2011;6:724-32
30 High bapwv and High bpep/bet are Associated with Rapid Renal Function Decline and Progression to Dialysis in CKD L bapwv L bapwv H bapwv H bapwv L bpep/bet H bpep/bet L bpep/bet H bpep/bet N=243, Stage 3-5 Chen & Chen, Hypertens Res 2012;35:
31 31 Four-Limb BP High BP is an established modifiable risk factor for cardiovascular disease and mortality. However, the association between BP and cardiovascular risk weakens in the elderly. J Hypertens 24: , 2006 A major confounding factor is atherosclerotic PAD. When PAD is present in subclavian and brachial arteries, arm BP cannot be accurately measured, and HT therefore cannot be timely diagnosed and properly managed in clinical practice. Lane D et al, J Hypertens 20: , 2002
32 32 Interarm BP Difference National Institute for Health and Clinical Excellence (NICE) clinical guideline for hypertension a difference of < 10 mmhg can be regarded as normal a difference of > 20 mmhg between arms is unusual occur in less than 4% of people usually associated with underlying vascular disease
33 33 Interarm BP Difference is associated with PAOD and LVH N=1120 Su & Chen, PLoS One 2012;7:e41173
34 Interleg BP Difference Predicts Overall and CV Mortality in HD 34 Normal Interleg BP D. Normal Interleg BP D. log-rank P<0.001 log-rank P<0.001 Interleg Diffe. of SBP 15mmHg or DBP 10mmHg Interleg Diffe. of SBP 15mmHg or DBP 10mmHg Overall Survival N=110, Follow up 4.4±1.5y Cardiovascular Survival Chen & Chen, CJASN 2012;7:
35 35 Interankle SBP Difference is Associated with a 25% Decline in egfr Interankle SBP D. 6mmHg log-rank p = Interankle SBP D. 6mmHg N=1445, Stage 3-5, Follow 3.1y Chen & Chen, Nephrology 2016;21:379-86
36 Overhydration is Associated with Progression to RRT in CKD 36 N=472, Stage 4-5, Follow 17.3m Tsai & Chen, AJKD 2014;63:68-75
37 Overhydration is Associated with Overall and CV Mortality in CKD 37 Entire Cohort N=478 HS<7% N=239 HS 7% N=239 P-value Patient-year of follow-up <0.001 Combined outcomes per 100 patient-year (95%CI) 8.6 ( ) 4.4( ) 14.3( ) <0.001 Cardiovascular morbidity per 100 patient-year (95%CI) 6.7( ) 3.0( ) 11.5( ) <0.001 Death per 100 patient-year (95%CI) 3.3( ) 1.4( ) 5.8( ) Data are expressed as number (percentage) for categorical variables and median (25 th, 75 th percentile) for continuous variables, as appropriate. Abbreviations: HS, relative hydration status P-value was measured by comparisons between participants with HS 7% and those with HS<7%. N=478, Stage 4-5, Follow 23.2m Tsai & Chen, CJASN 2015;10:39-46
38 38 Heart Rate Variability (HRV) Heart rate variability (HRV) is used to evaluate the cardiovascular autonomic neuropathy. HRV is defined as variations of both instantaneous heart rate and R-R intervals of ECG. HRV may provide a simple and noninvasive way in assessing the activities of the autonomic nervous system. HRV has been categorized into high-frequency (HF) and low-frequency (LF) ranges. Normalized LF(LF%) is considered to mirror the sympatho-vagal balance or to reflect sympathetic modulation.
39 39 Some HRV Parameters Increased in Patients without Peripheral Artery Disease (PAD) in HD HRV parameters (frequency domain) Without PAD With PAD Before HD After HD Before HD After HD LF (ms 2 ) 2.5 ± ± ± ± 0.6 HF (ms 2 ) 2.3 ± ± 0.4 * 1.6 ± ± 0.7 LF% (nu) 42.2 ± ± 2.0 * 35.3 ± ± 3.4 HF% (nu) 33.0 ± ± ± ± 1.9 LF/HF 0.22± ± 0.10 * ± ± 0.16 N=161 HD Chen & Chen, PLoS One 2015;10:e
40 LF%(Normalized Low Frequency for HRV) Predicts Overall and CV Survival in HD 40 p = p = Overall Survival N=182 HD, Follow 35.2m Cardiovascular Survival Chen & Chen, Sci Rep 2016;6:20597
41 41 Cholesterol Iseki K et al, Kidney Int 2002; 61 :
42 Cholesterol is Associated with Renal Outcomes in CKD 42 Renal replacement therapy Rapid renal progression Unadjusted Adjusted Unadjusted Adjusted Total cholesterol HR (95% CI) HR (95% CI) OR (95% CI) OR (95% CI) Quintile (1.10, 1.61)* 1.23 (1.01, 1.49)* 1.12 (0.86, 1.46) 1.06 (0.79, 1.42) Quintile Quintile (0.74, 1.10) 1.08 (0.88, 1.33) 1.05 (0.81, 1.38) 1.17 (0.87, 1.57) Quintile (0.95, 1.39) 1.25 (1.02, 1.52)* 1.18 (0.90, 1.54) 1.20 (0.89, 1.61) Quintile (1.13, 1.64)* 1.35 (1.11, 1.65)* 1.98 (1.53, 2.55)* 1.36 (1.01, 1.83)* *p < 0.05; **p < compared to quintile 2 N=3,303, Stage 3-5, Follow 2.8y Chen & Chen, PLoS One 2013;8:e55643
43 Proteinuria Modify the Relationship Between Lipid Profile and Mortality in CKD 43 TC & TC/HDL-- Overall mortality if UPr<1g/D TC/HDL-- Overall mortality if UPr 1g/D N=3,303, Stage 3-5, Follow 2.8y Chen & Chen, CJASN 2013 ;8:
44 4 4 Summary Cardiovascular diseases are common in CKD, and CKD has been recognized as a major risk factor for CVD. Many nontraditional risk factors also contribute to CVD and should not be missed. We should recognize patients at risk and provide early prevention and treatment.
45 Thank you for your attention
HTA ET DIALYSE DR ALAIN GUERIN
HTA ET DIALYSE DR ALAIN GUERIN Cardiovascular Disease Mortality General Population vs ESRD Dialysis Patients 100 Annual CVD Mortality (%) 10 1 0.1 0.01 0.001 25-34 35-44 45-54 55-64 66-74 75-84 >85 Age
More informationCoronary artery disease (CAD) risk factors
Background Coronary artery disease (CAD) risk factors CAD Risk factors Hypertension Insulin resistance /diabetes Dyslipidemia Smoking /Obesity Male gender/ Old age Atherosclerosis Arterial stiffness precedes
More informationEffects of Kidney Disease on Cardiovascular Morbidity and Mortality
Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Joachim H. Ix, MD, MAS Assistant Professor in Residence Division of Nephrology University of California San Diego, and Veterans Affairs
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationBlood Pressure Monitoring in Chronic Kidney Disease
Blood Pressure Monitoring in Chronic Kidney Disease Aldo J. Peixoto, MD FASN FASH Associate Professor of Medicine (Nephrology), YSM Associate Chief of Medicine, VACT Director of Hypertension, VACT American
More informationOptimal blood pressure targets in chronic kidney disease
Optimal blood pressure targets in chronic kidney disease Pr. Michel Burnier Service of Nephrology and Hypertension University Hospital Lausanne Switzerland Evidence-Based Guideline for the Management
More informationArterial Pressure in CKD5 - ESRD Population Gérard M. London
Arterial Pressure in CKD5 - ESRD Population Gérard M. London INSERM U970 Paris 150 SBP & DBP by Age, Ethnicity &Gender (US Population Age 18 Years, NHANES III) 150 SBP (mm Hg) 130 110 80 Non-Hispanic Black
More informationSeung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine
Seung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine The Scope of Optimal BP BP Reduction CV outcomes & mortality CKD progression - Albuminuria - egfr decline
More informationTable 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use
Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use Baseline characteristics Users (n = 28) Non-users (n = 32) P value Age (years) 67.8 (9.4) 68.4 (8.5)
More informationEarly Detection of Damaged Organ
Early Detection of Damaged Organ Regional Cardiovascular Center, Chungbuk National University Kyung-Kuk Hwang Contents NICE guideline 2011 - Confirm the diagnosis of HT ambulatory blood pressure monitoring
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu Indicator area: Pulse rhythm assessment for AF Indicator: NM146 Date: June 2017 Introduction There is evidence
More informationTHE IMPACT OF CCB AND RAS INHIBITOR COMBINATION THERAPY TO PREVENT CKD INCIDENCE IN HYPERTENSION AND ADVANCED ATHEROSCLEROSIS
THE IMPACT OF CCB AND RAS INHIBITOR COMBINATION THERAPY TO PREVENT CKD INCIDENCE IN HYPERTENSION AND ADVANCED ATHEROSCLEROSIS Daisuke MAEBUCHI, Yasuyuki SHIRAISHI, Hiroaki TANAKA, Yumiko INUI, Makoto TAKEI,
More informationARTERIAL STIFFNESS ASSESSMENT COMMENTS:
ARTERIAL STIFFNESS ASSESSMENT 10% Low small artery stiffness risk. However, we detect mild vasoconstriction in small artery. No large arterial stiffness has been detected. High Blood Pressure & Arterial
More informationAllopurinol reduces left ventricular hypertrophy and endothelial dysfunction in patients with chronic kidney disease
Allopurinol reduces left ventricular hypertrophy and endothelial dysfunction in patients with chronic kidney disease Michelle P Kao, Donald S Ang, Steve Gandy, Chim C Lang, Allan D Struthers Division of
More informationKDIGO LESSONS LEARNED FROM NEPHROLOGY TRIALS WITH RESPECT TO HEART FAILURE
LESSONS LEARNED FROM NEPHROLOGY TRIALS WITH RESPECT TO HEART FAILURE Dr. Christopher T Chan Director Division of Nephrology University Health Network Professor of Medicine University of Toronto Disclosure
More informationTrial to Reduce. Aranesp* Therapy. Cardiovascular Events with
Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,
More informationCARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES
CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES C. Liakos, 1 G. Vyssoulis, 1 E. Karpanou, 2 S-M. Kyvelou, 1 V. Tzamou, 1 A. Michaelides, 1 A. Triantafyllou, 1 P. Spanos, 1 C. Stefanadis
More informationPrevention of Atrial Fibrillation and Heart Failure in the Hypertensive Patient
Prevention of Atrial Fibrillation and Heart Failure in the Hypertensive Patient The Issue of Primary Prevention of A.Fib. (and Heart Failure) and not the Prevention of Recurrent A.Fib. after Electroconversion
More informationSystolic Blood Pressure Intervention Trial (SPRINT)
09:30-09:50 2016.4.15 Systolic Blood Pressure Intervention Trial (SPRINT) IN A NEPHROLOGIST S VIEW Sejoong Kim Seoul National University Bundang Hospital Current guidelines for BP control Lowering BP
More informationMetabolic Syndrome and Chronic Kidney Disease
Metabolic Syndrome and Chronic Kidney Disease Definition of Metabolic Syndrome National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Abdominal obesity, defined as a waist circumference
More informationNephrology Unit- CHU Liège- Ulg- Belgium
Are the complications of arteriovenous fistulas associated with an abnormal Ankle-Brachial Index in Hemodialysis? A 4y study P. Xhignesse, A. Saint-Remy, B. Dubois, JC. Philips, JM. Krzesinski Nephrology
More informationThe earlier BP control the better cardiovascular outcome. Jin Oh Na Cardiovascular center Korea University Medical College
The earlier BP control the better cardiovascular outcome Jin Oh Na Cardiovascular center Korea University Medical College Index Introduction HOPE-3 Trial Sprint Study Summary Each 2 mmhg decrease in SBP
More informationChapter 4: Cardiovascular Disease in Patients With CKD
Chapter 4: Cardiovascular Disease in Patients With CKD The prevalence of cardiovascular disease is 68.8% among patients aged 66 and older who have CKD, compared to 34.1% among those who do not have CKD
More informationEffects of Renin-Angiotensin System blockade on arterial stiffness and function. Gérard M. LONDON Manhès Hospital Paris, France
Effects of Renin-Angiotensin System blockade on arterial stiffness and function Gérard M. LONDON Manhès Hospital Paris, France Determinants of vascular overload (afterload) on the heart Peripheral Resistance
More informationDISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE
ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal
More informationNomogram of the Relation of Brachial-Ankle Pulse Wave Velocity with Blood Pressure
801 Original Article Nomogram of the Relation of Brachial-Ankle Pulse Wave Velocity with Blood Pressure Akira YAMASHINA, Hirofumi TOMIYAMA, Tomio ARAI, Yutaka KOJI, Minoru YAMBE, Hiroaki MOTOBE, Zydem
More informationFelix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study
Felix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study Conflict of interest disclosure None Committee of Scientific Affairs Committee
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationCKD and risk management : NICE guideline
CKD and risk management : NICE guideline 2008-2014 Shahed Ahmed Consultant Nephrologist shahed.ahmed@rlbuht.nhs.uk Key points : Changing parameters of CKD and NICE guidance CKD and age related change of
More informationHypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town
Hypertension targets: sorting out the confusion Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Historical Perspective The most famous casualty of this approach was the
More informationCorrelation between Left Atrial Diameter and Renal Outcomes in Chronic Kidney Disease Patients
Acta Nephrologica 27(1): 23-30, 2013 23 DOI: 10.6221/AN.2012018 Original Article Correlation between Left Atrial Diameter and Renal Outcomes in Chronic Kidney Disease Patients Tsung-Kun Yang 1, Szu-Chia
More informationCentral pressures and prediction of cardiovascular events in erectile dysfunction patients
Central pressures and prediction of cardiovascular events in erectile dysfunction patients N. Ioakeimidis, K. Rokkas, A. Angelis, Z. Kratiras, M. Abdelrasoul, C. Georgakopoulos, D. Terentes-Printzios,
More informationsurtout qui n est PAS à risque?
3*25 min et surtout qui n est PAS à risque? 2018 ESC/ESH Hypertension Guidelines 2018 ESC-ESH Guidelines for the Management of Arterial Hypertension 28 th ESH Meeting on Hypertension and Cardiovascular
More informationCardiovascular Risk Reduction in Kidney Transplant Recipients
Cardiovascular Risk Reduction in Kidney Transplant Recipients Rainer Oberbauer R.O. AUG 2010 CV Mortality in ESRD compared to the general population R.O.2/32 Modified from Foley et al. AJKD 32 (suppl3):
More informationEchocardiography analysis in renal transplant recipients
Original Research Article Echocardiography analysis in renal transplant recipients S.A.K. Noor Mohamed 1*, Edwin Fernando 2, 1 Assistant Professor, 2 Professor Department of Nephrology, Govt. Stanley Medical
More informationThe organs of the human body were created to perform ten functions among which is the function of the kidney to furnish the human being with thought.
The organs of the human body were created to perform ten functions among which is the function of the kidney to furnish the human being with thought. Leviticus Rabba 3 Talmud Berochoth 6 1 b Outline &
More informationCardiovascular Mortality: General Population vs ESRD Dialysis Patients
Cardiovascular Mortality: General Population vs ESRD Dialysis Patients Annual CVD Mortality (%) 100 10 1 0.1 0.01 0.001 25-34 35-44 45-54 55-64 66-74 75-84 >85 Age (years) GP Male GP Female GP Black GP
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationHeart Failure in Women: Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre
Heart Failure in Women: More than EF? Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre Overview Review pathophysiology as it relates to diagnosis and management Rational approach to workup:
More informationInterventions to reduce progression of CKD what is the evidence? John Feehally
Interventions to reduce progression of CKD what is the evidence? John Feehally Interventions to reduce progression of CKD what is the evidence? CHALLENGES Understanding what we know. NOT.what we think
More informationCARDIO-RENAL SYNDROME
CARDIO-RENAL SYNDROME Luis M Ruilope Athens, October 216 DISCLOSURES: ADVISOR/SPEAKER for Astra-Zeneca, Bayer, BMS, Daiichi-Sankyo, Esteve, GSK Janssen, Lacer, Medtronic, MSD, Novartis, Pfizer, Relypsa,
More informationDiagnosis is it really Heart Failure?
ESC Congress Munich - 25-29 August 2012 Heart Failure with Preserved Ejection Fraction From Bench to Bedside Diagnosis is it really Heart Failure? Prof. Burkert Pieske Department of Cardiology Med.University
More informationT. Suithichaiyakul Cardiomed Chula
T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial
More informationInsulin resistance influences 24h heart rate and blood pressure variabilities and cardiovascular autonomic modulation in normotensive healthy adults
Insulin resistance influences 24h heart rate and blood pressure variabilities and cardiovascular autonomic modulation in normotensive healthy adults Ochoa JE 1, Correa M 2, Valencia AM 2, Gallo J 2, McEwen
More informationUpdate on Current Trends in Hypertension Management
Friday General Session Update on Current Trends in Hypertension Management Shawna Nesbitt, MD Associate Dean, Minority Student Affairs Associate Professor, Department of Internal Medicine Office of Student
More informationhypertension Head of prevention and control of CVD disease office Ministry of heath
hypertension t. Samavat MD,Cadiologist,MPH Head of prevention and control of CVD disease office Ministry of heath RECOMMENDATIONS FOR HYPERTENSION DIAGNOSIS, ASSESSMENT, AND TREATMENT Definition of hypertension
More informationCardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center
Cardiovascular Disease in CKD Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center Objectives Describe prevalence for cardiovascular disease in CKD
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Table S1: Number and percentage of patients by age category Distribution of age Age
More informationHypertension in Geriatrics. Dr. Allen Liu Consultant Nephrologist 10 September 2016
Hypertension in Geriatrics Dr. Allen Liu Consultant Nephrologist 10 September 2016 Annual mortality (%) Cardiovascular Mortality Rates are Higher among Dialysis Patients 100 10 1 0.1 0.01 0.001 25-34
More informationD Terentes-Printzios, C Vlachopoulos, G Vyssoulis, N Ioakeimidis, P Xaplanteris, K Aznaouridis, E Christoforatou, A Samentzas, A Siama, C Stefanadis
Peripheral Vessels Unit, 1st Department of Cardiology Athens Medical School Hippokration Hospital, Athens, Greece D Terentes-Printzios, C Vlachopoulos, G Vyssoulis, N Ioakeimidis, P Xaplanteris, K Aznaouridis,
More informationIndividual Study Table Referring to Part of Dossier: Volume: Page:
Synopsis Abbott Laboratories Name of Study Drug: Paricalcitol Capsules (ABT-358) (Zemplar ) Name of Active Ingredient: Paricalcitol Individual Study Table Referring to Part of Dossier: Volume: Page: (For
More informationPredicting and changing the future for people with CKD
Predicting and changing the future for people with CKD I. David Weiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University
More informationEstrogens vs Testosterone for cardiovascular health and longevity
Estrogens vs Testosterone for cardiovascular health and longevity Panagiota Pietri, MD, PhD, FESC Director of Hypertension Unit Athens Medical Center Athens, Greece Women vs Men Is there a difference in
More informationImportance of Ambulatory Blood Pressure Monitoring in Adolescents
Importance of Ambulatory Blood Pressure Monitoring in Adolescents Josep Redon, MD, PhD, FAHA Internal Medicine Hospital Clinico Universitario de Valencia University of Valencia CIBERObn Instituto de Salud
More informationCauses of death in Diabetes
Rates of CV events in Diabetes patients Respiratory4.2 Cancer 7.6 Diabetes 1.3 CV disease 17.3 Causes of death in Diabetes 250 200 150 100 50 0 per 10,000 person-years 97 151 243 Framingham 5 X increase
More informationEPIDEMIOLOGY OF ARRHYTHMIAS AND OUTCOMES IN CKD & DIALYSIS KDIGO. Wolfgang C. Winkelmayer, MD, ScD Baylor College of Medicine Houston, Texas
EPIDEMIOLOGY OF ARRHYTHMIAS AND OUTCOMES IN CKD & DIALYSIS Wolfgang C. Winkelmayer, MD, ScD Baylor College of Medicine Houston, Texas Disclosure of Interests AstraZeneca (scientific advisory board) Bayer
More informationTodd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM
Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM Faculty Disclosure I have no financial interest to disclose No off-label use of medications will be discussed FIFTH ANNUAL SYMPOSIUM Recognize changes between
More informationWhen should you treat blood pressure in the young?
ESC Stockholm - Dilemmas in Cardiovascular Disease Prevention in the Young: 30 th August 2010 When should you treat blood pressure in the young? Bryan Williams MD FRCP FAHA FESC Professor of Medicine Department
More informationSerum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic
Supplementary Information The title of the manuscript Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic stroke Xin-Wei He 1, Wei-Ling Li 1, Cai Li
More informationARIC Manuscript Proposal # PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority:
ARIC Manuscript Proposal # 1475 PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority: 1.a. Full Title: Hypertension, left ventricular hypertrophy, and risk of incident hospitalized
More informationAssociation between arterial stiffness and cardiovascular risk factors in a pediatric population
+ Association between arterial stiffness and cardiovascular risk factors in a pediatric population Maria Perticone Department of Experimental and Clinical Medicine University Magna Graecia of Catanzaro
More informationModule 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension
Module 2 Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension 1 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
More informationVA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005
VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,
More informationGuest Speaker Evaluations Viewer Call-In Thanks to our Sponsors: Phone: Fax: Public Health Live T 2 B 2
Public Health Live T 2 B 2 Chronic Kidney Disease in Diabetes: Early Identification and Intervention Guest Speaker Joseph Vassalotti, MD, FASN Chief Medical Officer National Kidney Foundation Thanks to
More information4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?
HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL
More informationVascular disease. Structural evaluation of vascular disease. Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital
Vascular disease. Structural evaluation of vascular disease Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital resistance vessels : arteries
More informationHYPERTENSION AND HEART FAILURE
HYPERTENSION AND HEART FAILURE Kenya Cardiac Society Symposium Feb 2017 Dr Jeilan Mohamed No conflict of interests . Geoffrey, 45 yr old hypertensive office worker male from Nairobi, has just watched his
More informationTheoretical and practical questions in the evaluation of arterial function Miklós Illyés MD. Ph.D.
Theoretical and practical questions in the evaluation of arterial function Miklós Illyés MD. Ph.D. TensioMed Arterial Stiffness Centre, Budapest Heart Institute, Faculty of Medicine, University of Pécs
More informationJNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH
JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977
More informationHypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
More informationThe New Hypertension Guidelines
The New Hypertension Guidelines Joseph Saseen, PharmD Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Disclosure Joseph Saseen reports no conflicts
More informationRelationship between Arterial Stiffness and the Risk of Coronary Artery Disease in Subjects with and without Metabolic Syndrome
243 Original Article Hypertens Res Vol.30 (2007) No.3 p.243-247 Relationship between Arterial Stiffness and the Risk of Coronary Artery Disease in Subjects with and without Metabolic Syndrome Yutaka KOJI
More informationChapter 4: Cardiovascular Disease in Patients with CKD
Chapter 4: Cardiovascular Disease in Patients with CKD The prevalence of cardiovascular disease (CVD) was 65.8% among patients aged 66 and older who had chronic kidney disease (CKD), compared to 31.9%
More informationCentral hemodynamics and prediction of cardiovascular events in patients with erectile dysfunction
Central hemodynamics and prediction of cardiovascular events in patients with erectile dysfunction N.Skliros, N.Ioakeimidis, D.Terentes-Printzios, C.Vlachopoulos Cardiovascular Diseases and Sexual Health
More informationTotal risk management of Cardiovascular diseases Nobuhiro Yamada
Nobuhiro Yamada The worldwide burden of cardiovascular diseases (WHO) To prevent cardiovascular diseases Beyond LDL Multiple risk factors With common molecular basis The Current Burden of CVD CVD is responsible
More informationApproach to patient with hypertension. Dr. Amitesh Aggarwal
Approach to patient with hypertension Dr. Amitesh Aggarwal Definition A systolic blood pressure ( SBP) >139 mmhg and/or A diastolic (DBP) >89 mmhg. Based on the average of two or more properly measured,
More informationHypertension Management in Diabetic Patients
Hypertension Management in Diabetic Patients Park, Chang G, MD, PhD Cardiovascular Center, Guro Hospital, Korea University Medical School Contents (Treatment of 2 Cases) Type 2 Diabetes Mellitus Hypertension
More informationMorbidity & Mortality from Chronic Kidney Disease
Morbidity & Mortality from Chronic Kidney Disease Dr. Lam Man-Fai ( 林萬斐醫生 ) Honorary Clinical Assistant Professor MBBS, MRCP, FHKCP, FHKAM, PDipID (HK), FRCP (Edin, Glasg) Hong Kong Renal Registry Report
More informationHFpEF, Mito or Realidad?
HFpEF, Mito or Realidad? Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Associate Chief for Academic Affairs -- Cardiology Montefiore-Einstein Medical Center Bronx, NY
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationEARLY DETECTION OF DIABETES COMPLICATIONS AUTONOMIC NERVOUS SYSTEM AND VASCULAR FUNCTION ASSESSMENTS
HIGHLY REIMBURSABLE M A K I N G A D I F F E R E N C E EARLY DETECTION OF DIABETES COMPLICATIONS AUTONOMIC NERVOUS SYSTEM AND VASCULAR FUNCTION ASSESSMENTS BLOOD PRESSURE AND ARTERIAL STIFFNESS ANALYSIS
More informationTargeting vascular damage (stiffness, calcifications) in CKD: beyond blood pressure
Targeting vascular damage (stiffness, calcifications) in CKD: beyond blood pressure Should we still measure BP in dialysis? Clinical Problems with cuff BP Case #1: Variances in Cuff BP vs. Central BP 140/80
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationTreatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2014 Update on Randomized Trials
Treatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2014 Update on Randomized Trials Marc A. Pfeffer, MD, PhD; Brian Claggett, PhD; Susan F. Assmann,
More informationOutcomes of dialysis in the elderly. DNT March 2011 Dr Céline Foote
Outcomes of dialysis in the elderly DNT March 2011 Dr Céline Foote Increasing number of elderly patients on renal replacement therapy 500 500 Patients per million 400 300 200 100 400 300 200 100 TOTAL
More informationSupplementary Online Content. Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and
1 Supplementary Online Content 2 3 4 5 6 Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and cardiometabolic risk factor management on sympton burden and severity in patients with atrial
More informationΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH
ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH Hypertension Co-Morbidities HTN Commonly Clusters with Other Risk
More informationImproved survival of type 2 diabetic patients on renal replacement therapy in Finland
Nephrol Dial Transplant (2010) 25: 892 896 doi: 10.1093/ndt/gfp555 Advance Access publication 21 October 2009 Improved survival of type 2 diabetic patients on renal replacement therapy in Finland Marjo
More informationNew Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD
New Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD None Disclosures Objectives Understand trend in blood pressure clinical practice guidelines
More informationBackground. Metabolic syndrome T2DM CARDIOVASCULAR DISEASE. Major Unmet Clinical Need. Novel Risk Factors. Classical Risk Factors LDL-C.
The effect of metabolic syndrome for left ventricular geometry, arterial stiffness and carotid intima-media thickness in Korean general population Result from Atherosclerosis RIsk of Rural Area in Korea
More informationHypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute
Hypertension Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension 2017 Classification BP Category Systolic Diastolic Normal 120 and 80 Elevated
More informationClinical application of Arterial stiffness. pulse wave analysis pulse wave velocity
Clinical application of Arterial stiffness pulse wave analysis pulse wave velocity Arterial system 1. Large arteries: elastic arteries Aorta, carotid, iliac, Buffering reserve: store blood during systole
More informationEgyptian Hypertension Guidelines
Egyptian Hypertension Guidelines 2014 Egyptian Hypertension Guidelines Dalia R. ElRemissy, MD Lecturer of Cardiovascular Medicine Cairo University Why Egyptian Guidelines? Guidelines developed for rich
More informationPrevention of Cardiovascular Disease
Save Thais from Heart Diseases 2019 Prevention of Cardiovascular Disease Orawan Anupraiwan, MD. Central Chest Institute of Thailand ASCVD Prevention Pyramid Risk categories Very high-risk High-risk Documented
More informationLD TECHNOLOGY PRODUCT CATALOG
LD TECHNOLOGY M A K I N G A D I F F E R E N C E EARLY DETECTION OF DIABETES COMPLICATIONS AUTONOMIC NERVOUS SYSTEM AND VASCULAR FUNCTION ASSESSMENTS BLOOD PRESSURE AND ARTERIAL STIFFNESS ANALYSIS Monitoring
More informationYuqing Zhang, M.D., FESC Department of Cardiology, Fu Wai Hospital. CAMS & PUMC, Beijing, China
What Can We Learn from the Observational Studies and Clinical Trials of Prehypertension? Yuqing Zhang, M.D., FESC Department of Cardiology, Fu Wai Hospital. CAMS & PUMC, Beijing, China At ARIC visit 4
More informationBlood Pressure Treatment Goals
Blood Pressure Treatment Goals Kenneth Izuora, MD, MBA, FACE Associate Professor UNLV School of Medicine November 18, 2017 Learning Objectives Discuss the recent studies on treating hypertension Review
More informationThe Author(s) This article is published with open access by ASEAN Federation of Cardiology
DOI 10.7603/s40602-014-0011-3 ASEAN Heart Journal http://www.aseanheartjournal.org/ Vol. 22, no. 1, 60 65 (2014) ISSN: 2315-4551 Erratum Erratum to: Impact Of Sex On Clinical Characteristics And In-Hospital
More informationDepartments of Cardiology and Vascular Surgery Michaelidion Cardiac Center University of Ioannina, Greece
Departments of Cardiology and Vascular Surgery Michaelidion Cardiac Center University of Ioannina, Greece ARGYRIS Vassilis, PEROULIS Michalis, MATSAGKAS Miltiadis, BECHLIOULIS Aris, MICHALIS Lampros, NAKA
More information